Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.84 |
| ▸ | BRAF | P15056 | 19/20 | 0.70 |
| ▸ | EGFR | P00533 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18922160 | 1.00 | RAF1 (0.84) | RAF1BRAFEGFR | |
| SCHEMBL16379948 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL18922180 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL15085291 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL15085286 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL17800204 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL16380189 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL30584457 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL22279526 | 0.92 | RAF1 (1.00) | RAF1BRAFEGFR | |
| SCHEMBL20614995 | 0.89 | RAF1 (0.82) | RAF1BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2020-02-18 | — | — | US | disclosed |
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2019-02-19 | — | — | US | disclosed |
| US-9920055-B2 | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2018-03-20 | — | — | US | disclosed |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9670203-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885EGFR 248/4885 |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885EGFR 248/4885 |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885EGFR 248/4885 |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885EGFR 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.